Which has better earnings and valuation, ATOS or ALZN?

Atossa Genetics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.11 N/A Alzamend Neuro N/A N/A -$8.77M -$2.30 N/A

Is ATOS or ALZN more profitable?

Atossa Genetics' return on equity of -102.99% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Alzamend Neuro N/A -277.88% -184.20%

Is KYNB or ALZN more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Alzamend Neuro's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -47.27% Alzamend Neuro N/A -277.88% -184.20%

Which has preferable valuation & earnings, ALZN or NXTC?

NextCure is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$8.77M -$2.30 N/A NextCure N/A N/A -$55.84M -$8.70 N/A

Is ALZN or NXTC more profitable?

NextCure's return on equity of -154.62% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -277.88% -184.20% NextCure N/A -154.62% -100.19%

Which has preferable earnings and valuation, JSPR or ALZN?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A Alzamend Neuro N/A N/A -$8.77M -$2.30 N/A

Is JSPR or ALZN more profitable?

Alzamend Neuro's return on equity of -277.88% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Alzamend Neuro N/A -277.88% -184.20%

Which has preferable earnings & valuation, ALZN or RADX?

Alzamend Neuro has higher earnings, but lower revenue than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$8.77M -$2.30 N/A Radiopharm Theranostics $1.88M 9.44 -$38.65M N/A N/A

Is ALZN or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -277.88% -184.20% Radiopharm Theranostics N/A N/A N/A

Alzamend Neuro (ALZN) Competitors

$1.34 0.00 (0.00%)

Closing price 10/9/2026 03:56 PM Eastern

Extended Trading

$1.34 -0.01 (-0.37%)

As of 10/9/2026 04:10 PM Eastern

Compare

ALZN vs. ATOS, KYNB, NXTC, JSPR, and RADX

Should you buy Alzamend Neuro stock or one of its competitors? Alzamend Neuro's main competitors and comparable companies include Atossa Genetics (ATOS), Kyntra Bio (KYNB), NextCure (NXTC), Jasper Therapeutics (JSPR), and Radiopharm Theranostics (RADX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alzamend Neuro compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Atossa Genetics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Atossa Genetics' return on equity of -102.99% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Alzamend Neuro	N/A	-277.88%	-184.20%

In the previous week, Atossa Genetics had 10 more articles in the media than Alzamend Neuro. MarketBeat recorded 11 mentions for Atossa Genetics and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.41 beat Atossa Genetics' score of 0.89 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Atossa Genetics	Positive
Alzamend Neuro	Positive

Atossa Genetics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Atossa Genetics presently has a consensus price target of $20.33, suggesting a potential upside of 733.33%. Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 1,989.55%. Given Alzamend Neuro's higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Atossa Genetics beats Alzamend Neuro on 7 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kyntra Bio has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Kyntra Bio has higher revenue and earnings than Alzamend Neuro. Alzamend Neuro is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	3.84	$183.45M	$45.30	0.13
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A

Kyntra Bio has a net margin of 2,199.13% compared to Alzamend Neuro's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Alzamend Neuro	N/A	-277.88%	-184.20%

In the previous week, Kyntra Bio had 2 more articles in the media than Alzamend Neuro. MarketBeat recorded 3 mentions for Kyntra Bio and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.41 beat Kyntra Bio's score of 0.61 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Kyntra Bio	Positive
Alzamend Neuro	Positive

Kyntra Bio presently has a consensus price target of $37.25, suggesting a potential upside of 509.66%. Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 1,989.55%. Given Alzamend Neuro's higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Kyntra Bio beats Alzamend Neuro on 13 of the 15 factors compared between the two stocks.

How does Alzamend Neuro compare to NextCure?

Alzamend Neuro (NASDAQ:ALZN) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by company insiders. Comparatively, 11.9% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NextCure is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

Alzamend Neuro currently has a consensus price target of $28.00, suggesting a potential upside of 1,989.55%. NextCure has a consensus price target of $19.00, suggesting a potential upside of 164.62%. Given Alzamend Neuro's higher probable upside, research analysts clearly believe Alzamend Neuro is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

NextCure's return on equity of -154.62% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.88%	-184.20%
NextCure	N/A	-154.62%	-100.19%

Alzamend Neuro has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, NextCure has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

In the previous week, NextCure had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 2 mentions for NextCure and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.41 beat NextCure's score of 0.27 indicating that Alzamend Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
Alzamend Neuro	Positive
NextCure	Neutral

Summary

NextCure beats Alzamend Neuro on 7 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Jasper Therapeutics has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Alzamend Neuro's return on equity of -277.88% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Alzamend Neuro	N/A	-277.88%	-184.20%

In the previous week, Jasper Therapeutics had 2 more articles in the media than Alzamend Neuro. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.41 beat Jasper Therapeutics' score of 0.54 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Positive
Alzamend Neuro	Positive

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 3.9% of Jasper Therapeutics shares are held by insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alzamend Neuro is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A

Jasper Therapeutics presently has a consensus target price of $7.33, indicating a potential upside of 1,186.10%. Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 1,989.55%. Given Alzamend Neuro's higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Jasper Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Jasper Therapeutics beats Alzamend Neuro on 9 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Radiopharm Theranostics?

Alzamend Neuro (NASDAQ:ALZN) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Alzamend Neuro presently has a consensus price target of $28.00, indicating a potential upside of 1,989.55%. Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 873.45%. Given Alzamend Neuro's higher probable upside, equities research analysts clearly believe Alzamend Neuro is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Radiopharm Theranostics had 2 more articles in the media than Alzamend Neuro. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.41 beat Radiopharm Theranostics' score of 0.61 indicating that Alzamend Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
Alzamend Neuro	Positive
Radiopharm Theranostics	Positive

Radiopharm Theranostics' return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.88%	-184.20%
Radiopharm Theranostics	N/A	N/A	N/A

49.6% of Alzamend Neuro shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alzamend Neuro has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

Alzamend Neuro has higher earnings, but lower revenue than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A
Radiopharm Theranostics	$1.88M	9.44	-$38.65M	N/A	N/A

Summary

Radiopharm Theranostics beats Alzamend Neuro on 7 of the 12 factors compared between the two stocks.

Get Alzamend Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALZN vs. The Competition

Export

Metric	Alzamend Neuro	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.47M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-0.58	13.55	275.01	26.14
Price / Sales	N/A	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	7.05	17.17	11.22	6.33
Net Income	-$8.77M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-2.19%	-1.34%	-0.89%	-1.40%
1 Month Performance	-22.09%	-8.04%	-4.02%	-3.35%
1 Year Performance	-38.53%	14.18%	7.13%	1.49%

Alzamend Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALZN Alzamend Neuro	3.445 of 5 stars	$1.34 flat	$28.00 +1,989.6%	-38.5%	$6.47M	N/A	N/A	6	News Coverage Positive News Gap Up
ATOS Atossa Genetics	2.229 of 5 stars	$2.45 flat	$20.33 +729.9%	-84.9%	$24.45M	N/A	N/A	14	News Coverage Analyst Revision
KYNB Kyntra Bio	3.7789 of 5 stars	$5.97 +0.2%	$37.25 +523.6%	N/A	$24.08M	$6.44M	0.13	570	News Coverage Analyst Downgrade Gap Up
NXTC NextCure	2.7687 of 5 stars	$6.00 +5.6%	$19.00 +216.7%	+8.0%	$21.66M	N/A	N/A	40	Analyst Upgrade Short Interest Increase
JSPR Jasper Therapeutics	1.6881 of 5 stars	$0.59 +4.4%	$7.33 +1,153.6%	-76.2%	$19.30M	N/A	N/A	22	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALZN) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alzamend Neuro (ALZN) Competitors

ALZN vs. ATOS, KYNB, NXTC, JSPR, and RADX

How does Alzamend Neuro compare to Atossa Genetics?

Summary

How does Alzamend Neuro compare to Kyntra Bio?

Summary

How does Alzamend Neuro compare to NextCure?

Summary

How does Alzamend Neuro compare to Jasper Therapeutics?

Summary

How does Alzamend Neuro compare to Radiopharm Theranostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alzamend Neuro (ALZN) Competitors

ALZN vs. ATOS, KYNB, NXTC, JSPR, and RADX

How does Alzamend Neuro compare to Atossa Genetics?

Which has more risk & volatility, ATOS or ALZN?

Is ATOS or ALZN more profitable?

Does the media favor ATOS or ALZN?

Which has better earnings and valuation, ATOS or ALZN?

Do insiders and institutionals have more ownership in ATOS or ALZN?

Do analysts prefer ATOS or ALZN?

Summary

How does Alzamend Neuro compare to Kyntra Bio?

Do insiders and institutionals have more ownership in KYNB or ALZN?

Which has more volatility and risk, KYNB or ALZN?

Which has higher earnings & valuation, KYNB or ALZN?

Is KYNB or ALZN more profitable?

Does the media prefer KYNB or ALZN?

Do analysts rate KYNB or ALZN?

Summary

How does Alzamend Neuro compare to NextCure?

Do insiders & institutionals hold more shares of ALZN or NXTC?

Which has preferable valuation & earnings, ALZN or NXTC?

Do analysts prefer ALZN or NXTC?

Is ALZN or NXTC more profitable?

Which has more volatility and risk, ALZN or NXTC?

Does the media prefer ALZN or NXTC?

Summary

How does Alzamend Neuro compare to Jasper Therapeutics?

Which has more volatility and risk, JSPR or ALZN?

Is JSPR or ALZN more profitable?

Does the media prefer JSPR or ALZN?

Do institutionals & insiders believe in JSPR or ALZN?

Which has preferable earnings and valuation, JSPR or ALZN?

Do analysts recommend JSPR or ALZN?

Summary

How does Alzamend Neuro compare to Radiopharm Theranostics?

Do analysts prefer ALZN or RADX?

Does the media refer more to ALZN or RADX?

Is ALZN or RADX more profitable?

Do institutionals and insiders believe in ALZN or RADX?

Which has more volatility and risk, ALZN or RADX?

Which has preferable earnings & valuation, ALZN or RADX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools